AML1 haploinsufficiency results in a decrease in LTR-HSCs
Cell number* . | AML1+/+ mice + for donor engraftment/total mice . | AML1+/- mice + for donor engraftment/total mice . |
|---|---|---|
| 200 000 | 5/5† | 8/8 |
| 100 000 | 5/5 | 5/5 |
| 32 000 | 10/10 | 14/16 |
| 16 000 | 11/12 | 8/15 |
| 8 000 | 3/12 | 1/15 |
| 4 000 | 5/16 | 1/6 |
| 2 000 | 0/6 | 0/6 |
| LTR-HSCs | 1 in 11 171 ± 2509‡ | 1 in 22 878 ± 5102 |
Cell number* . | AML1+/+ mice + for donor engraftment/total mice . | AML1+/- mice + for donor engraftment/total mice . |
|---|---|---|
| 200 000 | 5/5† | 8/8 |
| 100 000 | 5/5 | 5/5 |
| 32 000 | 10/10 | 14/16 |
| 16 000 | 11/12 | 8/15 |
| 8 000 | 3/12 | 1/15 |
| 4 000 | 5/16 | 1/6 |
| 2 000 | 0/6 | 0/6 |
| LTR-HSCs | 1 in 11 171 ± 2509‡ | 1 in 22 878 ± 5102 |
Results represent 2 independent experiments, with a mixture of BM cells from 2 to 3 donor mice used in each experiment.
Number of “test” BM cells from AML1+/+ or +/- mice injected into each recipient.
Mice positive for donor engraftment were defined as those with more than 1% Ly5.2+ cells in the peripheral blood by FACS in both the lymphoid and myeloid gates as assessed by forward and side scatter.
The LTR-HSC frequency was calculated by Poisson statistics. The difference between AML1+/+ and +/- was statistically significant (P = .006).